Causes of death in 2877 patients with myelodysplastic syndromes

被引:69
作者
Nachtkamp, Kathrin [1 ]
Stark, Romina [1 ]
Strupp, Corinna [1 ]
Kuendgen, Andrea [1 ]
Giagounidis, Aristoteles [2 ]
Aul, Carlo [2 ]
Hildebrandt, Barbara [3 ]
Haas, Rainer [1 ]
Gattermann, Norbert [1 ]
Germing, Ulrich [1 ]
机构
[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] St Johannes Hosp, Dept Hematol Oncol & Clin Immunol, Duisburg, Germany
[3] Univ Dusseldorf, Dept Human Genet, Dusseldorf, Germany
关键词
Myelodysplastic syndromes; Causes of death; Prognosis; PROGNOSTIC SCORING SYSTEM; CLASSIFICATION; COMORBIDITY; VALIDATION; PROPOSALS;
D O I
10.1007/s00277-016-2649-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with myelodysplastic syndromes face a poor prognosis. The exact causes of death have not been described properly in the past. We performed a retrospective analysis of causes of death using data of 3792 patients in the Dusseldorf registry who have been followed up for a median time of 21 months. Medical files as well as death certificates were screened and primary care physicians were contacted. Death after AML evolution, infection, and bleeding was considered to be clearly disease-related. Further categories of causes of death were heart failure, other possibly disease-related reasons, such as hemochromatosis, disease-independent reasons as well as cases with unclear causes of death. Median age at the time of diagnosis was 71 years. At the time of analysis, 2877 patients (75.9 %) had deceased. In 1212 cases (42.1 %), the exact cause of death could not be ascertained. From 1665 patients with a clearly documented cause of death, 1388 patients (83.4 %) succumbed directly disease-related (AML (46.6 %), infection (27.0 %), bleeding (9.8 %)), whereas 277 patients (16.6 %) died for reasons not directly related with myelodysplastic syndromes (MDS), including 132 patients with cardiac failure, 77 non-disease-related reasons, 23 patients with solid tumors, and 45 patients with possibly disease-related causes like hemochromatosis. Correlation with IPSS, IPSS-R, and WPSS categories showed a proportional increase of disease-related causes of death with increasing IPSS/IPSS-R/WPSS risk category. Likewise, therapy-related MDS were associated with a higher percentage of disease-related causes of death than primary MDS. This reflects the increasing influence of the underlying disease on the cause of death with increasing aggressiveness of the disease.
引用
收藏
页码:937 / 944
页数:8
相关论文
共 15 条
  • [1] AUL C, 1992, LEUKEMIA, V6, P52
  • [2] Brunning RD., 2008, WHO CLASSIFICATION T, V4tH ed lARC, P87
  • [3] Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome
    Dayyani, Farshid
    Conley, Anthony P.
    Strom, Sara S.
    Stevenson, William
    Cortes, Jorge E.
    Borthakur, Gautam
    Fader, Stefan
    O'Brien, Susan
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. CANCER, 2010, 116 (09) : 2174 - 2179
  • [4] Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
    de Swart, Louise
    Smith, Alex
    Johnston, Thomas W.
    Haase, Detlef
    Droste, Jackie
    Fenaux, Pierre
    Symeonidis, Argiris
    Sanz, Guillermo
    Hellstroem-Lindberg, Eva
    Cermak, Jaroslav
    Germing, Ulrich
    Stauder, Reinhard
    Georgescu, Otilia
    MacKenzie, Marius
    Malcovati, Luca
    Holm, Mette S.
    Almeida, Antonio M.
    Madry, Krzysztof
    Slama, Borhane
    Guerci-Bresler, Agnes
    Sanhes, Laurence
    Beyne-Rauzy, Odile
    Luno, Elisa
    Bowen, David
    de Witte, Theo
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) : 372 - 383
  • [5] Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool
    Della Porta, Matteo G.
    Ambaglio, Ilaria
    Ubezio, Marta
    Travaglino, Erica
    Pascutto, Cristiana
    Malcovati, Luca
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04): : 631 - 632
  • [6] Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
    Della Porta, Matteo G.
    Malcovati, Luca
    Strupp, Corinna
    Ambaglio, Ilaria
    Kuendgen, Andrea
    Zipperer, Esther
    Travaglino, Erica
    Invernizzi, Rosangela
    Pascutto, Cristiana
    Lazzarino, Mario
    Germing, Ulrich
    Cazzola, Mario
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03): : 441 - 449
  • [7] Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients
    Germing, U
    Gattermann, N
    Strupp, C
    Aivado, M
    Aul, C
    [J]. LEUKEMIA RESEARCH, 2000, 24 (12) : 983 - 992
  • [8] Germing U, 2006, HAEMATOLOGICA, V91, P1596
  • [9] International scoring system for evaluating prognosis in myelodysplastic syndromes
    Greenberg, P
    Cox, C
    LeBeau, MM
    Fenaux, P
    Morel, P
    Sanz, G
    Sanz, M
    Vallespi, T
    Hamblin, T
    Oscier, D
    Ohyashiki, K
    Toyama, K
    Aul, C
    Mufti, G
    Bennett, J
    [J]. BLOOD, 1997, 89 (06) : 2079 - 2088
  • [10] Revised International Prognostic Scoring System for Myelodysplastic Syndromes
    Greenberg, Peter L.
    Tuechler, Heinz
    Schanz, Julie
    Sanz, Guillermo
    Garcia-Manero, Guillermo
    Sole, Francesc
    Bennett, John M.
    Bowen, David
    Fenaux, Pierre
    Dreyfus, Francois
    Kantarjian, Hagop
    Kuendgen, Andrea
    Levis, Alessandro
    Malcovati, Luca
    Cazzola, Mario
    Cermak, Jaroslav
    Fonatsch, Christa
    Le Beau, Michelle M.
    Slovak, Marilyn L.
    Krieger, Otto
    Luebbert, Michael
    Maciejewski, Jaroslaw
    Magalhaes, Silvia M. M.
    Miyazaki, Yasushi
    Pfeilstoecker, Michael
    Sekeres, Mikkael
    Sperr, Wolfgang R.
    Stauder, Reinhard
    Tauro, Sudhir
    Valent, Peter
    Vallespi, Teresa
    van de Loosdrecht, Arjan A.
    Germing, Ulrich
    Haase, Detlef
    [J]. BLOOD, 2012, 120 (12) : 2454 - 2465